VALNEVA SE (VLA.PA)

FR0004056851 - Common Stock

3.591  -0.03 (-0.77%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VLA. VLA was compared to 79 industry peers in the Biotechnology industry. VLA may be in some trouble as it scores bad on both profitability and health. VLA is quite expensive at the moment. It does show a decent growth rate.



2

1. Profitability

1.1 Basic Checks

In the past year VLA has reported negative net income.
VLA had a negative operating cash flow in the past year.
In the past 5 years VLA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: VLA reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -11.37%, VLA is in the better half of the industry, outperforming 68.92% of the companies in the same industry.
With a decent Return On Equity value of -37.57%, VLA is doing good in the industry, outperforming 60.81% of the companies in the same industry.
Industry RankSector Rank
ROA -11.37%
ROE -37.57%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 39.95%, VLA is doing good in the industry, outperforming 62.16% of the companies in the same industry.
VLA's Gross Margin has declined in the last couple of years.
VLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%

2

2. Health

2.1 Basic Checks

VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for VLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

VLA has an Altman-Z score of -0.02. This is a bad value and indicates that VLA is not financially healthy and even has some risk of bankruptcy.
VLA has a Altman-Z score (-0.02) which is in line with its industry peers.
A Debt/Equity ratio of 0.86 indicates that VLA is somewhat dependend on debt financing.
VLA's Debt to Equity ratio of 0.86 is in line compared to the rest of the industry. VLA outperforms 43.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -0.02
ROIC/WACCN/A
WACC6.51%

2.3 Liquidity

A Current Ratio of 1.47 indicates that VLA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.47, VLA is not doing good in the industry: 67.57% of the companies in the same industry are doing better.
VLA has a Quick Ratio of 1.30. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.30, VLA is doing worse than 66.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.3

4

3. Growth

3.1 Past

VLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.13%, which is quite impressive.
The Revenue for VLA has decreased by -27.77% in the past year. This is quite bad
Measured over the past years, VLA shows a small growth in Revenue. The Revenue has been growing by 6.34% on average per year.
EPS 1Y (TTM)41.13%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-137.88%
Revenue 1Y (TTM)-27.77%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Revenue growth Q2Q-75.7%

3.2 Future

The Earnings Per Share is expected to grow by 26.58% on average over the next years. This is a very strong growth
Based on estimates for the next years, VLA will show a quite strong growth in Revenue. The Revenue will grow by 19.73% on average per year.
EPS Next Y132.28%
EPS Next 2Y26.58%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.77%
Revenue Next 2Y13.39%
Revenue Next 3Y32.4%
Revenue Next 5Y19.73%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VLA. In the last year negative earnings were reported.
VLA is valuated correctly with a Price/Forward Earnings ratio of 15.24.
Based on the Price/Forward Earnings ratio, VLA is valued cheaper than 81.08% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.74, VLA is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 15.24

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VLA's earnings are expected to grow with 26.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.58%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for VLA!.
Industry RankSector Rank
Dividend Yield N/A

VALNEVA SE

EPA:VLA (3/27/2024, 7:00:00 PM)

3.591

-0.03 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap249.19M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.24
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.37%
ROE -37.57%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 39.95%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.47
Quick Ratio 1.3
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)41.13%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y132.28%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-27.77%
Revenue growth 3Y11.69%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y